نتایج جستجو برای: pomalidomide
تعداد نتایج: 497 فیلتر نتایج به سال:
Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma patients. The aim of the work herein was to investigate the activity of filanesib in combination with pomalidomide plus dexamethasone backbone, and the mechanisms underly...
We thank D’Amato et al. (1) and Zeldis et al. (2) for their interest and comments on our article in PNAS (3). We carried out a screen of lenalidomide and pomalidomide primarily in chicken and zebrafish embryos, but also in several in vitro assays. Our goal was to determine any differential actions or responses and to visualize effects live and in vivo (3). Identifying such differences, we reaso...
Lenalidomide and pomalidomide have both been evaluated clinically for their properties as anticancer agents, with lenalidomide being available commercially. We previously reported that both compounds cause cell cycle arrest in Burkitt's lymphoma and multiple myeloma cell lines by increasing the level of p21(WAF-1) expression. In the present study, we unravel the molecular mechanism responsible ...
mTOR is a protein kinase that plays a central role in regulating critical cellular processes. We evaluated the activation and cellular localization of the mTOR pathway in multiple myeloma (MM) and analyzed the role of pomalidomide in regulating mTOR. By immunohistochemistry cytoplasmic p-mTOR stained positive in 57 out 101 (57.6%) cases with a nuclear p-mTOR localization in 14 out 101 samples (...
Although lenalidomide and pomalidomide are well-established treatment options in patients with multiple myeloma, their immune-modulating effects are not fully understood. While CD8+CD28- regulatory T-cells in patients with hematologic disorders display a known immune-escape mechanism, we show that lenalidomide can overcome the immunosuppressive impact of CD8+CD28- T-cells. We analyzed in vitro ...
Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 pat...
Cereblon, a member of the cullin 4 ring ligase complex (CRL4), is the molecular target of the immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide and is required for the antiproliferative activity of these agents in multiple myeloma (MM) and immunomodulatory activity in T cells. Cereblon's central role as a target of lenalidomide and pomalidomide suggests potential utility as a predict...
Lenalidomide is a highly effective treatment for multiple myeloma, other B-cell neoplasms including mantle cell lymphoma and chronic lymphocytic leukemia, and myelodysplastic syndrome (MDS) with del(5q). Lenalidomide is a derivative of thalidomide, infamous for its teratogenicity following use as an anti-emetic in pregnant women. Thalidomide, lenalidomide, and another derivative, pomalidomide (...
Recent discoveries suggest that the critical events leading to the anti-proliferative activity of the IMiD immunomodulatory agents lenalidomide and pomalidomide in multiple myeloma (MM) cells are initiated by Cereblon-dependent ubiquitination and proteasomal degradation of substrate proteins Ikaros (IKZF1) and Aiolos (IKZF3). By performing kinetic analyses, we found that the downregulation or p...
Usage of non-ionic contrast agents in patients with multiple myeloma, who have normal creatinine level, is not high risk to develop contrast-induced nephropathy. Novel agents has improved prognosis of patients with myeloma but immunomodulatory drug-containing therapy such as lenalidomide and pomalidomide has a risk of venous thromboembolism (VTE) and pulmonary embolism (PE). Contrast-enhanced C...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید